Tysabri labeling changes submitted to help stratify PML risk

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Tysabri labeling changes submitted to help stratify PML risk

Postby MSUK » Wed Dec 22, 2010 1:47 am

Image

Biogen Idec and Elan Corporation, plc have announced that the companies have submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMA) to request review and approval to update the respective Tysabri Prescribing Information and Summary of Product Characteristics.

The companies are proposing updated product labeling to include anti-JC Virus antibody status as one potential factor to help stratify the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection, in the Tysabri-treated population.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2105
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Tysabri (Antegren or Natalizumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users